Valuation : Structure Therapeutics Inc.

Market Cap 3.36B 2.9B 2.73B 2.48B 4.67B 319B 4.7B 32.24B 12.55B 162B 12.62B 12.34B 538B P/E 2026 *
-29.1x
P/E 2027 * -21.6x
Enterprise Value 2.39B 2.06B 1.94B 1.77B 3.33B 227B 3.35B 22.96B 8.94B 116B 8.99B 8.79B 383B EV / Sales 2026 *
62.2x
EV / Sales 2027 * 67,234x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day+2.73%
1 week-5.59%
Current month+2.66%
1 month-1.89%
3 months+22.26%
6 months-25.17%
Current year-32.24%
1 week 45.1
Extreme 45.1
49.81
1 month 45.1
Extreme 45.1
55.6
Current year 35.78
Extreme 35.78
94.77
1 year 18.49
Extreme 18.49
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Operating Officer 49 15/04/2026
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 A Exercice

Chief Technology Officer

43,329 0.0310%
8/4/26 A Exercice

Chief Technology Officer

43,329 0.0310%
7/22/26 A
F-Prime Inc.
OtherCompany 17,452 0.0101%
Change 5-day change 1-year change 3-year change Capi.($)
+2.82%-5.59%+144.20%+60.47% 3.36B
-0.25%-4.10%+38.38%+92.61% 68.21B
+4.22%+2.58%+51.95%+93.89% 64.25B
+3.23%-1.92%-10.72%+436.70% 26.54B
+3.31%-10.61%+1.95%-16.27% 25.61B
+3.17%+1.62%+32.81%-17.61% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.65%-5.28%-1.12%+534.90% 14.93B
+3.69%+0.30%+52.03%+150.18% 14.1B
+2.23%+5.18%+23.04%+190.97% 12.45B
Average +1.50%-4.09%+55.86%+190.09% 26.65B
Weighted average by Cap. +1.61%-3.25%+44.04%+158.68%

Financials

2026 *2027 *
Net sales 38.46M 33.18M 31.21M 28.43M 53.46M 3.65B 53.75M 369M 144M 1.86B 144M 141M 6.16B 41.67K 35.94K 33.81K 30.8K 57.92K 3.95M 58.24K 400K 156K 2.01M 156K 153K 6.67M
Net income -309M -266M -250M -228M -429M -29.28B -431M -2.96B -1.15B -14.89B -1.16B -1.13B -49.39B -475M -410M -386M -351M -661M -45.11B -664M -4.56B -1.77B -22.95B -1.78B -1.75B -76.09B
Net Debt -967M -834M -785M -715M -1.34B -91.79B -1.35B -9.28B -3.61B -46.69B -3.63B -3.55B -155B -559M -482M -454M -413M -777M -53.07B -782M -5.36B -2.09B -27B -2.1B -2.05B -89.52B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
02/09/26 $47.76 +1.34% 8,705
01/09/26 $47.13 +2.66% 816,626
31/08/26 $45.91 -3.08% 1,394,959
28/08/26 $47.37 -3.76% 601,773
27/08/26 $49.22 -0.26% 318,921
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
47.13USD
Average target price
104.77USD
Spread / Average Target
+122.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock